Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid

Ann Hematol. 2007 Apr;86(4):295-7. doi: 10.1007/s00277-006-0219-9. Epub 2006 Nov 30.

Authors

Vincenza Martini, Clara Minotti, Massimo Breccia, Gioia De Angelis, Sonia Buffolino, Montano Mariella, Francesco Lo-Coco, Giuseppe Avvisati, Giuseppe Cimino

PMID: 17136541
DOI: 10.1007/s00277-006-0219-9

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aminoglycosides / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / therapeutic use
Arsenic Trioxide
Arsenicals / therapeutic use
Cardiomyopathies / complications*
Cardiomyopathies / pathology
Cardiomyopathies / physiopathology
Drug Therapy, Combination
Echocardiography
Gemtuzumab
Humans
Leukemia, Promyelocytic, Acute / complications
Leukemia, Promyelocytic, Acute / drug therapy*
Leukemia, Promyelocytic, Acute / genetics
Male
Middle Aged
Oncogene Proteins, Fusion / genetics
Oxides / therapeutic use
Remission Induction
Reverse Transcriptase Polymerase Chain Reaction
Treatment Outcome
Tretinoin / therapeutic use*

Substances

Aminoglycosides
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Arsenicals
Oncogene Proteins, Fusion
Oxides
promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
Tretinoin
Gemtuzumab
Arsenic Trioxide